InMed Pharmaceuticals (INM) Free Cash Flow (QoQ) (2019 - 2026)
InMed Pharmaceuticals (INM) Free Cash Flow (QoQ) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.88 Bn | 87.01 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn |
| 3 | Zoetis | 32.31 Bn | 30.37 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.92 Bn | 16.61 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn |
| 10 | InMed Pharmaceuticals | 6.98 Mn | 1.74 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.66% |
| Dec 31, 2025 | -47.81% |
| Sep 30, 2025 | 9.61% |
| Jun 30, 2025 | -7.17% |
| Mar 31, 2025 | 33.68% |
| Dec 31, 2024 | -36.97% |
| Sep 30, 2024 | -77.50% |
| Jun 30, 2024 | 47.18% |
| Mar 31, 2024 | -5.53% |
| Dec 31, 2023 | 14.96% |
| Sep 30, 2023 | -163.66% |
| Jun 30, 2023 | 50.29% |
| Mar 31, 2023 | 38.94% |
| Dec 31, 2022 | -20.58% |
| Sep 30, 2022 | 45.32% |
| Jun 30, 2022 | 23.05% |
| Mar 31, 2022 | -63.17% |
| Dec 31, 2021 | -12.87% |
| Sep 30, 2021 | -45.66% |
| Jun 30, 2021 | 56.77% |